Display Settings:

Format

Send to:

Choose Destination
    Curr Opin Pharmacol. 2008 Apr;8(2):114-9. Epub 2008 Mar 4.

    The neurokinin 1 receptor: a potential new target for anti-platelet therapy?

    Source

    School of Biological Sciences, University of Reading, Whiteknights, Reading, Berkshire RG6 6AJ, UK. j.m.gibbins@reading.ac.uk

    Abstract

    The important role of platelets in the development of arterial thrombosis and cardiovascular disease is well established. Current treatments for arterial thrombosis include anti-platelet agents such as aspirin, thienopyridines and glycoprotein IIb-IIIa inhibitors. Despite these drugs being effective there remains a substantial unmet clinical demand for more effective therapeutic approaches, which may reflect the existence of alternative underlying regulatory mechanisms to those already targeted. Recent publications have demonstrated a key role for tachykinins in the positive feedback regulation of platelet aggregation and thrombus formation. The pro-thrombotic effects of tachykinins on platelets are mediated through the neurokinin 1 receptor, which may therefore offer a novel therapeutic drug target in the prevention and the treatment of arterial thrombosis.

    PMID:
    18296119
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Elsevier Science

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk